Home > News > PSivida losses almost all due to R&D
August 30th, 2004
PSivida losses almost all due to R&D
Abstract:
pSivida Limited (PSD) today reported that after deducting outside equity interest they had recorded a loss attributable to the members of pSivida of $3.6 million for financial year ending 30 June 2004, compared to a loss of $2.7 million in 2003. The consolidated entity of the global nanotechnology company incurred a net loss of $7.5 million, compared to $5.3 million in 2003. The operating loss includes $7,million in research and development costs expended by pSiMedica and administrative expenses totalling $888,961.
Source:
egoli
Bookmark:
Financial Reports
Nanobiotix Revenue for the 1st quarter of 2013 May 15th, 2013
Harris & Harris Group Reports Financial Statements as of March 31, 2013 May 10th, 2013
Arrowhead Reports Fiscal 2013 Second Quarter Financial Results - Conference Call Today at 4:30 p.m. Eastern Time May 9th, 2013
Arrowhead to Report Fiscal 2013 Second Quarter Financial Results - Conference Call Scheduled for Thursday, May 9, 2013 May 2nd, 2013